Publications found:
50,761
Sort by:
Future US Microbiology Testing Market Outlook
US$ 7,520.00
Highlights Comprehensive 1,037-page analysis of the US microbiology testing market. Major issues pertaining to the US microbiology laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current ...
February 2012
1037 pages
Future US Transfusion Diagnostic Testing Market Outlook
US$ 7,120.00
Highlights Comprehensive 460-pages market segmentation analysis of the US transfusion testing market. Major issues pertaining to the US transfusion testing practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...
February 2012
460 pages
GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!
US$ 140.00
Gilead (GILD) is poised for further growth, based on the FY12 ... GILD a step closer towards its goal to deliver the “best-in-class IFN-free oral pill” for HCV. Other acquisitions ... read our report released on 10th Feb., 2012 on Gilead Sciences titled “Providing the Best Antiviral Treatment Options for HIV and HCV!”
February 2012
11 pages
AMGEN - Still Worth Holding!
US$ 90.00
Amgen (AMGN) has sufficient cash (total cash: $19.6b, Lt. Debt: $21.4b) and experience to ... -up, it is still trading at a favorable multiple against its peers. For more details, please read our report released on 9th Feb., 2012 titled “Still worth Holding!”
February 2012
7 pages
BIOGEN IDEC - Investing for Long-Term
US$ 140.00
Biogen Idec (BIIB) promises to enrich its revenue stream and MS franchise in 2012 ... detail, please read our report released on 8th Feb., 2012 on Biogen Idec titled “Investing for Long-Term”.
February 2012
9 pages
Drug Industry in the United States - Porter’s Five Forces Strategy Analysis
US$ 175.00
... falling, leading to layoffs and cuts in research budgets. While the US drug industry is hardly in a full-blown crisis, however, layoffs are occurring ... taken once a week instead of daily. Aruvian's R'search analyzes the United States Drug Industry in the Michael Porter’s Five Forces Analysis. It uses concepts ...
February 2012
12 pages
Analyzing the Chemical Industry in United States
US$ 375.00
... the environment. Aruvian's R'search’s report Analyzing the Chemical Industry in United States researches the characteristics of the US chemical industry and the segments which, as a ... the reputation and pride for the US Chemical Industry globally and placing the United States at the top of the pecking order ...
February 2012
250 pages
Analyzing the US Cosmeceuticals Industry
US$ 300.00
... and rule. Aruvians Rsearch analyzes the US Cosmeceutical Industry in its research offering Analyzing the US Cosmeceuticals Industry. The report ... The various cosmeceuticals analyzed include hair care cosmeceuticals, skin care cosmeceuticals, injectable cosmeceuticals and other cosmeceuticals. Product ...
February 2012
80 pages
BMY 4Q-11 Results – Patent expiry pains reflecting in the guidance
US$ 90.00
Post today’s announcement of 4Q-11 results, we reiterate our underperform rating on BMY with a PT of $26. The 2012 EPS guidance range of $1.9 - $2.0 is ... reflective of the towering pressures, while valuation continues to remain soaring. BMY holds a promising HCV pipeline, but seems priced to perfection. Yeryoy ...
January 2012
1 pages
USA Biotechnology Directory 2012 - 2013
US$ 200.00
PDF version is dispatched within twenty-four hours after the purchase. The most comprehensive and accurate Directory of companies and executives in the USA biotechnology industry.
January 2012
-
USA Medical Devices & Diagnostics Companies 2012-2013
US$ 200.00
PDF version is dispatched within twenty-four hours after the purchase. The most comprehensive and accurate Directory of companies and executives in the USA medical devices & diagnostics industry.
January 2012
-
Innovative Technologies And Their Impact on the US Diagnostics Market
US$ 3,880.00
The next ten years will be marked by significant technological developments in health care and biotechnology, which will drastically change the assumptions ... The report explores the impact of the most significant technological developments of the next ten years and their impact on the U.S. in vitro diagnostics ...
January 2012
85 pages
Analyzing the Mining Industry in the United States
US$ 350.00
The United States mining industry is an important ... process in order to remain global leaders. The United States produces a wide variety of commodities from gold to ... R'search’s report – Analyzing the Mining Industry in the United States - explains the historical lineage of mining as instincts to search ...
January 2012
200 pages
US Mining Industry – Porter’s Five Forces Strategy Analysis
US$ 200.00
The United States mining industry is an important contributor to ... indirectly. Aruvian's R'search analyzes The US Mining Industry in Michael Porter’s Five Forces Analysis. It uses concepts ... competitive intensity and therefore attractiveness of a market. Porter referred to these forces as the microenvironment, to ...
January 2012
35 pages
Analyzing the Market for Nuclear Reactor Coolant Pumps in the US
US$ 500.00
... percent of the electricity in the United States. With the US being the biggest supplier of commercial nuclear power in the world, the demand ... itself. Aruvians Rsearch analyzes the US market for nuclear reactor coolant pumps in its research offering Analyzing the Market for Nuclear Reactor Coolant Pumps in ...
January 2012
170 pages
ARQULE - Positive Data in HCC is an Add-On!
US$ 140.00
Positive PhII data of Tivantinib (formerly ARQ-197, c-MET inhibitor) in ... raises expectations and the efficacy bar for Tivantinib. We remain positive on an approval of Tivantinib in its lead indication – NSCLC ... read our report released on 19th January, 2012 on ArQule titled “Positive Data in HCC is an Add-On!”
January 2012
3 pages
REGENERON – Eylea Sales Add a Sparkle to The Eye!
US$ 120.00
... and Avastin (off-label), Regeneron (REGN) overwhelmed all concerns of a “weak launch” of Eylea (VEGF Trap-Eye, L, ... Bill” model! Uptake at this pace should entitle Eylea to capture…. Moreover, CEO’s optimism around REGN’s ... released on 11th January, 2012 on Regeneron titled “Eylea Sales Add a Sparkle to The Eye!”
January 2012
6 pages
REGENERON - Eylea’s Litigation Settlement = Good Start to 2012!
US$ 90.00
Regeneron (REGN) settled its patent litigation with Genentech (Roche) over Eylea (VEGF Trap-Eye, L, partnered ... payments to Roche -$60m when cumulative US sales of Eylea reach $400m + will pay royalties of 4.75% on ... 6th January, 2012 on Regeneron titled “Eylea’s Litigation Settlement = Good Start to 2012!”
January 2012
6 pages
AVEO Pharma - PhIII, TIVO-1 Data and Reaction - No Surprise!
US$ 90.00
Data from TIVO-1, PhIII study (head-to-head study with ONXX’s Nexavar) of Tivozanib (formerly AV- ... details, please read our report released on 4th January, 2012 on AVEO pharma titled “PhIII, TIVO-1 Data and Reaction - No Surprise!”
January 2012
3 pages
US Telecom Industry Assessment & Forecasts 2011 - 2020
US$ 2,500.00
The US Telecom industry is a complex business with numerous segments, which has undergone strong growth over the past ten years. Recent history ... through the year 2020 to reach almost $1.2 trillion in revenue. As penetration of a number of Telecom categories reaches over 90%, growth over the next ten years ...
January 2012
45 pages
Charter Schools: Market Research Report
US$ 2,950.00
... collection of statistical anecdotes, market briefs, and concise summaries of research findings. Illustrated with 31 fact-rich market data tables, the report offers an aerial view of the Charter Schools industry in the US, identifies major short to medium term market ...
January 2012
128 pages
US Biotech Market Analysis
US$ 1,000.00
The US represents the world’s largest biotechnology market, leading with its innovation, extensive R&D, and regular company developments in various spheres of the biotechnology sector. On the back...
December 2011
65 pages
US Healthcare Market Outlook 2013
US$ 1,000.00
The US represents the world’s largest healthcare market, with a high annual healthcare spending. The growth in healthcare spending is mainly driven by high administrative costs, and expensive hospital...
December 2011
80 pages
US Cement Industry Analysis
US$ 1,000.00
US being the world's largest economy and one of the most dynamic construction markets provided a substantial platform to its cement industry for expansion over the last two decades. However, last few...
December 2011
70 pages
Outlook 2012 - Rising Stars - Innovators Deliver but Rewards Not Guranteed!
US$ 2,000.00
... continue to flow from the backyards of small research focused companies (Rising stars, RS) but commercial success of launched products is not assured despite patents ... Micromet (MITI) are our Top Picks for FY2012 in the Rising Stars Sector. Key drugs of ANTH and MITI target high unmet ...
December 2011
52 pages
Analyzing Base Metals in the United States
US$ 350.00
... in the US. Aruvians Rsearch analyzes the US base metals market in its research report Analyzing Base Metals in the United States. The report is a complete coverage of the base metals industry in the United States. In this in-depth ...
December 2011
60 pages
Outlook 2012 - Mature Biotech - Investing in Growth and Value buys!
US$ 2,000.00
... ’ in 2011! We expect a similar trend of acquisitions and in-licensing of better molecules in 2012 and beyond, as MB companies have robust cash flow to further leverage ... Gilead (GILD) are our Top Picks for FY2012 in the Mature Biotech Sector. BIIB’s focus and leadership in the MS market and positive ...
December 2011
46 pages
Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
US$ 90.00
Recent news about “possible acquisition of Onyx pharma” is not a surprise in light of the upcoming ... over Regorafenib (BAY73-4506, PhIII) with Bayer. Onyx product pipeline focuses only in oncology. We have ... released on 30th November, 2011 on Onyx pharma titled “M&A Rumors Fuel Investors Interest and Stock ...
November 2011
6 pages
AMGN - Old is Gold = Value Buy!
US$ 140.00
... philosophy to pursue “innovation” in a balanced way should keep shareholders interested in AMGN for long term. PhIII data from study ‘147 published ... more detail, please read our report released on 25th November on AMGN titled “AMGN - Old is Gold = Value Buy!”
November 2011
4 pages
Vertex – “Testing Time Ahead for INCIVEK - After 2013!”
US$ 140.00
... in 2014, would result in declining sales for INCIVEK/IFN combination. Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients ... read our report released on 25th November, 2011 on VRTX titled “Testing Time Ahead for INCIVEK - After 2013!”
November 2011
10 pages
US Glucose Monitoring Market Analysis
US$ 1,000.00
The US has a dominant share in the global diabetes market with 90-95% of the diabetic patients in the country suffering from type-II diabetes. Factors like, high prevalence of diabetes, rising aging p...
November 2011
55 pages
US Denim Jeans Market Report: 2011 Edition
US$ 700.00
... Old Navy are the topmost women’s denim brands in the US. The report analyzes the denim jeans industry in the US. Market trends like introduction of new concepts ...
November 2011
34 pages
US Pharmacy Benefit Management (PBM) Industry Report: 2011 Edition
US$ 800.00
... chronic condition has also risen. The report analyzes the US Pharmacy Benefit Management Industry. Rising drug prices, increasing drug utilization and prevalence ... , contracts for renewals of the major players and market share of PBM companies adjusted on the basis of acquisitions and contract shifts. This ...
November 2011
40 pages
PHARMASSET - "IFN-free Oral Option" for HCV- Sharing the Big Pie!
US$ 140.00
Pharmasset (VRUS) may enjoy the first mover advantage in the race to offer the first “IFN free all oral option” to HCV pts. However the window ... read our report released on Nov. 16th, 2011 on VRUS titled “IFN-free Oral Option” for HCV- Sharing the Big Pie!
November 2011
9 pages
BIOGEN IDEC - Data of BG-12 + Sales Growth Brighten 2012 Prospects
US$ 140.00
Biogen Idec (BIIB) is closing 2011 with a positive note and ... Copaxone (L, RRMS) share of the MS market. Moreover, PhIIb data readouts from SELECT trial of Daclizumab HYP (PhII, IL-2 alpha subunit ... read our report, released on Nov. 8, 2011 on “Biogen Idec - Data of BG-12 + Sales Growth Brighten 2012 Prospects”
November 2011
6 pages
Mature Biotech: 3Q11 Earnings Summary
US$ 90.00
In this note we summarize the 3Q earnings of Mature Biotech – ALXN, AMGN, BIIB, CELG, GILD, and ONXX. We continue to reiterate ... PhIII data in mCRC). For more details, please read our 3Q11 earnings’ summary report released on 4th Nov, 2011 on “Mature Biotech: 3Q11 Earnings Summary”.
November 2011
5 pages
